Cure8 research brief
Optimizing advanced therapies can lower the chance of primary non‑response or losing response over time; this review gives consensus guidance relevant to many people with IBD on biologics or small molecules. Therapeutic drug monitoring and dose optimization are highlighted as ways clinicians try to improve outcomes.
Clinicians treating IBD, patients on biologics or small molecules, and researchers interested in therapeutic optimization strategies.
The review covers optimization for anti-TNF agents, vedolizumab, anti-IL-12/23 and anti-IL-23 biologics, and small molecules (including JAK inhibitors and S1P modulators). It emphasizes therapeutic drug monitoring and dose adjustments as standard components of modern IBD care, while noting evidence strength differs by drug.
The abstract provides a consensus overview rather than new trial data; read the full article for specific drug-by-drug recommendations and evidence levels.
This entry is based on the article abstract (topical review and consensus statements). It summarizes the review scope but does not replace reading the full review for drug-specific guidance or evidence grading.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: ECCO
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients and clinicians using vedolizumab may be interested because the review links higher trough concentrations to better remission outcomes—most convincingly for endoscopic remission in UC—and provides descriptive...
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
Using TDM to optimize vedolizumab could improve outcomes but may raise treatment costs; patients and clinicians should know cost-effectiveness depends heavily on drug price and local healthcare thresholds.
